Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.

Part of amana, Inc., Orion Co., Ltd. is a Japanese company located in Tokyo. The firm provides photos, computer graphics and related visual content. On December 28, 2005 amana, Inc. acquired Orion Co., Ltd. for $3.59 million.

Orion World is a manufacturer of Orion Caramel and localized drops called Orion King Drops with four flavors, orange, pineapple, strawberry, and lemon. The company was established in 1956 by Lee Yang-Gu and is based in Seoul, Korea.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Carinopharm GmbH is a private company headquartered in Eime, Germany. The firm manufactures pharmaceutical products. It was founded in 2000. Andreas Landau is currently the CEO of the company.\nThe company says this about itself: CARINOPHARM GmbH was founded at the beginning of year 2000 by a team of highly experienced pharmaceutical managers with both entrepreneurial and innovation-driven know-how. Since the start up to today, CARINOPHARM is a pharmaceutical company specialized in hospital business, concentrating on therapies for the areas of cardiology, intensive care and emergency medicine. The company is distinguished by a broad portfolio of selected parenteral products for these indication areas, consisting of both originals and generics. In addition to this portfolio of parenteral drugs, Carinopharm offers a range of mostly topical preparations for different indications mainly in the field of dermatology. Our products are exclusively manufactured in the EU, with a large proportion produced directly in Germany.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Chengdu Giantech Hi-Technology Development Co., Ltd. engages in the research and development of drugs and the provision of related technical services, with focuses on the anti-tumour, cardiovascular, cerebrovascular, diabetic, and anti-fungal fields. The company was founded on September 18, 2000 and is headquartered in Chengdu, China.

Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. It operates through the following geographical segments: India, Africa, Asia, Europe, North America, Australia and South America. The company was founded on July 23, 1984 and is headquartered in Mumbai, India.

Part of Chengdu Giantech Hi-Technology Development Co., Ltd., Chengdu Sino-Strong Pharmaceutical Co. Ltd. is a Chinese company. The firm develops and manufactures pharmaceuticals.

Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. Qilu focuses on the development, manufacturing and marketing of generic drugs and active pharmaceutical ingredients(APIs) in therapeutic areas including but not limited to Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, and Ophthalmological Diseases. Qilu has more than 15,000 employees, 70% of whom have a college degree or above. Qilu Pharmaceutical consistently focuses on revolutionary development strategies guided by market demand and product innovation. Qilu has established extensive cooperation with domestic and international partners on multiple R&D projects. Devoted to the cultivation of talent, Qilu has invested in a highly qualified R&D team and efficient R&D capabilities. The 200+ new drug products successfully developed by Qilu constitutes as a large part of future production and sales for Qilu Pharmaceutical and partners. A number of technological achievements have garnered national and provincial scientific and technological progress awards for Qilu.

Part of Lepu Medical Technology (Beijing) Co., Ltd., Beijing Haihetian Technology Development Co., Ltd. is a Chinese company located in Beijing that develops medical technology. It was acquired by Ningbo Xinjingmao Investment Management Center LP.

Navinta operates as a generic pharmaceutical company founded in 2003 working as a development and commercialization of pharmaceutical products to treat patients with chronic and life-threatening diseases. They are developing a pipeline of dosage products that include analgesics, cardiovascular therapeutic agents, cytotoxic anticancer agents, and uniquely formulated oral dosage forms.

Jinan Kanghe Pharmaceutical Technology Co., Ltd., established on 2011-06-13, Business scope includes pharmaceutical,medical supplements,Healthy food,Technical development of fine chemical products,technology transfer,technical consulting,Technical Services;medicine,medical supplements,Fine Chemicals(Free of Hazardous Chemicals)processing;Non-academic vocational skills training;Chemical Products(Free of Hazardous Chemicals),Experimental equipment,medicine,Sales of health food;leasing of instruments and equipment;Import and export of goods and technology;Laboratory Equipment Testing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sialon Pharmaceutical Group Co., Ltd. (Changsha) Pharmaceutical R&D Center, established on 2015-07-07, The business scope includes carrying out business activities within the business scope of the affiliated enterprise.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Oriola-KD has a solid position in consumer and services business in the pharmaceutical markets in Sweden, Finland and Baltic countries. Oriola-KD offers expert advice on health and wellbeing and an extensive and high-quality selection of products in its own pharmacies. To healthcare operators, Oriola-KD provides wide service offering covering pharmaceutical distribution, branded products and other tailored services. Oriola-KD unites consumers and pharmaceutical companies in a unique way. Oriola-KD provides pharmaceutical companies an effective access to markets and improves consumers' wellbeing by ensuring that pharmaceuticals, health products and services are delivered in a safe and customer-friendly manner. Oriola-KD’s net sales for continuing operations in 2015 were approximately EUR 1.6 billion.

Xiamen Ampton Information Technology Co., Ltd., established on 2016-07-14, Business scope includes information system integration services;software development;Information Technology Consulting Services;Data Processing and Storage Services;IC Design;animation,comic design,make;Other unspecified information technology service industry(Items not subject to permit approval);other internet services(Items not subject to permit approval).

Tenax Therapeutics, Inc., is a pharmaceutical company. It focuses on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The firm owns the North American rights to develop and commercialize levosimendan and has recently released data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.